Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 352

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Open access
Zhou, Jun, Mahoney, Kathleen M., Giobbie-Hurder, Anita, Zhao, Fengmin, Lee, Sandra, Liao, Xiaoyun, Rodig, Scott, Li, Jingjing, Wu, Xinqi, Butterfield, Lisa H., Piesche, Matthias, Manos, Michael P., Eastman, Lauren M., Dranoff, Glenn, Freeman, Gordon J., Hodi, F. Stephen·2017·Cancer Immunology Research

Abstract

Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in patients with a variety of cancers. Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple myeloma. However, the regulatory roles and function of sPD-L1 particularly in connection with immune checkpoint blockade treatment are not fully understood. We identified four splice variants of PD-L1 in melanoma cells, and all of them are secreted. Secretion of sPD-L1 resulted from alternate splicing activities, cytokine induction, cell stress, cell injury, and cell death in melanoma cells. Pretreatment levels of sPD-L1 were elevated in stage IV melanoma patient sera compared with healthy donors. High pretreatment levels of sPD-L1 were associated with increased likelihood of progressive disease in patients treated by CTLA-4 or PD-1 blockade. Although changes in circulating sPD-L1 early after treatment could not distinguish responders from those with progressive disease, after five months of treatment by CTLA-4 or PD-1 blockade patients who had increased circulating sPD-L1 had greater likelihood of developing a partial response. Induction of sPD-L1 was associated with increased circulating cytokines after CTLA-4 blockade but not following PD-1 blockade. Circulating sPD-L1 is a prognostic biomarker that may predict outcomes for subgroups of patients receiving checkpoint inhibitors. Cancer Immunol Res; 5(6); 480–92. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0329

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 352

Metadata

Authors
Zhou, J., Mahoney, K. M., Giobbie-Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S., Li, J., Wu, X., Butterfield, L. H., Piesche, M., Manos, M. P., Eastman, L. M., Dranoff, G., Freeman, G. J., & Hodi, F. S.
Venue
Cancer Immunology Research
Published
2017-06-01
Volume
5
Issue
6
Pages
480-492
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2615907969
Cited by
352
References
15
FWCI
14.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. https://app.cochat.ai/papers/10.1158/2326-6066.cir-16-0329
The paper
Zhou, J., Mahoney, K. M., Giobbie-Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S., Li, J., Wu, X., Butterfield, L. H., Piesche, M., Manos, M. P., Eastman, L. M., Dranoff, G., Freeman, G. J., & Hodi, F. S. (2017). Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-16-0329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.